Surgical Research Projects
Trainee Projects
- Michael C. Wang, MD: AI-assisted Development of Small Molecule Degraders of NRF2Mut Protein for Cancer Therapy
- Ami Kalola, MD: Development of a murine model to investigate epigenetic and immunomodulatory treatments in pancreatic neuroendocrine tumors
- Emma Dragan, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
- Emily Hancin, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
- Hannah Hong, DO: Mechanistic Insights and Therapeutic Approaches to Peritoneal Metastasis of Ovarian Cancer
- Zachary Ladd, MS: Development of NRF2Mut inhibitors for NRF2Mut esophageal cancer
- T. Hess, MD: Identifying the role of NRF2 in non-small cell lung cancer differentiation and treatment
- Rachel Nation, MD: Development of a murine model to investigate epigenetic and immunomodulatory treatments in pancreatic neuroendocrine tumors
- Hannah Sofield, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
- Gena Topper, MD: Intraperitoneal epigenetic drug perfusion for colorectal cancer-associated peritoneal carcinomatosis
- Chelsea Katz, MD: The resistance to chemotherapy in high-grade serous ovarian cancer and the role of NRF2
- Zachary Ladd, MS: Development of NRF2Mut inhibitors for NRF2Mut esophageal cancer
- Matthew Moccia, MD: Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
- Hansa Joshi, MD: Identification of Molecular Pathways Associated with Non-Small Cell Lung Cancer Subtype Switching after Treatment
- Yazid Khalil Mo Ghanem, MD: Intraperitoneal epigenetic drug perfusion for colon cancer-associated peritoneal carcinomatosis
- Helen Toma, MD: Chemotherapy Resistance in Ovarian Cancer and the Role of NRF2
- Zena Saleh, MD: Epigenetic alterations are associated with gene silencing and immune infiltration in human PNET
- Zachary Ladd, BS: Development of novel NRF2 inhibitors
Faculty/Staff Projects
- Tao Gao, PhD:
- Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
- Weam Elbezanti, PharmB, MS, PhD:
- Epigenetic treatments and their effects on tumor microenvironment
- HIPEC with epigenetic drugs for peritoneal carcinomatosis of colorectal cancer
- The effect of histotripsy on immune activation and cancer eradication
- Hyun-Kyung Ko, PhD:
- Targeting c-Myc and IGFBP2 for gastric cancer therapy
- Oscar Pellon, PhD:
- Mechanism and therapy of sarcoma
- Chemoresistance in Ovarian Cancer and The Role of NRF2
- Boopathi Subramaniyan, M.Phil, PhD:
- NRF2-responsive kinases in esophageal squamous cell carcinoma
- Huan Li, PhD:
- Chemo- and radio-sensitization of cancer cells
- Yahui Li, MS:
- Lymphatic metastasis of esophageal squamous cell carcinoma
- Xiaoxin Luke Chen, MD, PhD:
- NRF2 in esophageal squamous cell carcinoma and alcohol-associated esophageal pathology
- Madeline Torres, MD:
- Mechanism and therapy of sarcoma
- Targeting c-Myc and IGFBP2 for gastric cancer therapy
- Young Ki Hong, MD:
- Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
- HIPEC with epigenetic drugs for peritoneal carcinomatosis of colorectal cancer
- Francis Spitz, MD:
- Target NRF2 for cancer therapy